Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Orchestra BioMed Holdings (OBIO) Revenue (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Revenue for 4 consecutive years, with $30.9 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 12120.16% to $30.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $33.5 million through Dec 2025, up 1169.22% year-over-year, with the annual reading at $33.5 million for FY2025, 1169.22% up from the prior year.
  • Revenue for Q4 2025 was $30.9 million at Orchestra BioMed Holdings, up from $861000.0 in the prior quarter.
  • The five-year high for Revenue was $30.9 million in Q4 2025, with the low at $253000.0 in Q4 2024.
  • Average Revenue over 4 years is $2.7 million, with a median of $863500.0 recorded in 2022.
  • The sharpest move saw Revenue plummeted 76.25% in 2023, then surged 12120.16% in 2025.
  • Over 4 years, Revenue stood at $1.1 million in 2022, then tumbled by 76.25% to $262000.0 in 2023, then dropped by 3.44% to $253000.0 in 2024, then soared by 12120.16% to $30.9 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $30.9 million, $861000.0, and $836000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.